StockData
Jupiter Neurosciences, Inc. logo

Jupiter Neurosciences, Inc. (JUNS) shareholders

JUNSNasdaqPharmaceutical PreparationsFiscal year ends December 31
Số liệu tài chính tới Q2 năm tài chính 2026, quý kết thúc ngày Jun 30, 2026Last filing: 10-Q on Nov 16, 2026Score 0/30
$1.52−0.18 (-10.59%)

Close on Nov 17, 2026Market cap $1.17MP/E –Yield –

Ownership

Institutional holdings as of Jun 30, 2026, from 13F filings

Held by institutions
2.2%
0M of 1M shares
Institutional holders
13
6 new, 3 sold out
Net institutional buying
-0M
In Q2 2026
Insider trades, 12 months
0 buys · 0 sales
Open-market trades only

Shares held by institutions

Holders of more than 5%

Latest Schedule 13D (active) or 13G (passive) filed by each holder

HolderShares% of classFilingAs of
Christer Rosén13,069,15539.50%13D (active)Nov 8, 2024
Marshall Hayward4,015,176–13D (active)Nov 8, 2024
Claes Wahlestedt3,333,81610.90%13D (active)Nov 8, 2024
Shaun Brothers2,038,9716.70%13D (active)Nov 8, 2024
Alexander Rosén1,789,1005.70%13D (active)Nov 8, 2024
PharmAla Biotech Holdings Inc.132,86710.10%13G (passive) amendmentSep 30, 2026
Orca Capital AG102,5648.40%13G (passive)Aug 21, 2026

Top institutional holders

13F holdings as of Jun 30, 2026

HolderShares% of JUNSValueChange% of portfolio
Jane Street Group, LLC7,1120.92%$114.25KNew0.00%
Virtu Financial LLC3,0830.40%$50.00K+2,9020.00%
Geode Capital Management, LLC2,0810.27%$33.44K−7410.00%
Vanguard Capital Management LLC1,7070.22%$27.40K−3,0920.00%
Vanguard Fiduciary Trust Co1,1220.15%$18.01K−490.00%
XTX Topco Ltd4370.06%$7.02KNew0.00%
Tower Research Capital LLC (TRC)3840.05%$6.17KNew0.00%
Northern Trust Corp3380.04%$5.43K–0.00%
StoneX Group Inc.2750.04%$5.68KNew0.00%
Level Four Advisory Services, LLC1330.02%$2.14KNew0.00%
Vestor Capital, LLC290.00%$557.00K−12,9170.03%
MidFirst Bank130.00%$214–0.00%
Citigroup Inc70.00%$117New0.00%

Institutional buying and selling by quarter

Positions opened, added to, reduced and closed by 13F filers

QuarterHoldersShares held% of sharesNew / addedReduced / closedShares boughtShares sold
Q2 2026130M2.2%6 / 14 / 30M0M
Q1 2026100M3.3%5 / 21 / 60M0M
Q4 2025120M1.1%5 / 51 / 20M0M
Q3 202590M2.4%7 / 11 / 00M0M
Q2 202520M0.1%0 / 02 / 50M0M
Q1 202570M0.7%5 / 20 / 10M0M
Q4 202430M0.0%3 / 00 / 00M0M

Officers, directors and major owners

People who filed Forms 3, 4 or 5 in the last two years

NameRoleShares owned% of sharesLatest filing
Marshall A. HaywardChief Scientific Officer, Director2,995,077388.93%Jul 13, 2026
Christer RosenCEO and Chairman, Director11,078,8921438.67%Jun 4, 2026
Alison D. SilvaPresident and COO, Director112,77714.64%Jun 4, 2026
Alexander Gustaf Erik RosenChief Administrative Officer617,41180.17%Jul 13, 2026
Saleem ElmasriChief Financial Officer66,2398.60%Jun 4, 2026
Andrew Jon CutlerDirector––Aug 5, 2026
Nicholas H. HemmerlyDirector95,55012.41%Jul 13, 2026
Julie B. KampfDirector82,87510.76%Jul 13, 2026
Holger WeisDirector96,58112.54%Jul 13, 2026
Tomas Jan PhilipsonDirector––Jul 1, 2026
Allison W. BradyDirector21,7502.82%Jun 5, 2026

Insider trades

Common stock transactions reported on Form 4, newest first

InsiderDateTransactionSharesPriceValueShares after
Marshall A. Hayward
Chief Scientific Officer, Director
Mar 2, 2026Option exercise+225,000––2,995,077
Christer Rosen
CEO and Chairman, Director, 10% owner
Jul 1, 2025Buy+3,100$1.02$3.16K11,078,892
Christer Rosen
CEO and Chairman, Director, 10% owner
Jul 1, 2025Buy+500$1.01$50511,075,792
Alison D. Silva
Pres + Chief Business Officer, Director
Jul 1, 2025Buy+250$1.03$258112,777
Alison D. Silva
Pres + Chief Business Officer, Director
Jul 1, 2025Buy+250$1.03$258112,277
Alison D. Silva
Pres + Chief Business Officer, Director
Jul 1, 2025Buy+250$1.03$258112,527
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 30, 2025Buy+250$1.04$260111,927
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 30, 2025Buy+250$1.03$258111,677
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 30, 2025Buy+250$1.02$255111
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 30, 2025Buy+100$1.02$102111,177
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 30, 2025Buy+100$1.05$105112,027
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+1,450$1.02$1.48K11,072,092
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+1,000$0.98$98011,068,642
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+2,000$1.01$2.02K11,070,642
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+700$1.03$72111,072,792
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+1,500$1.04$1.56K11,074,292
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 30, 2025Buy+1,000$1.05$1.05K11,075,292
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 27, 2025Buy+250$1.05$263111,077
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 27, 2025Buy+250$1.04$260110,827
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 27, 2025Buy+100$1.04$104110,577
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 27, 2025Buy+250$1.00$250110,477
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 27, 2025Buy+166$1.06$17611,067,642
Nicholas H. Hemmerly
Director
Jun 2, 2025Option exercise+95,550––95,550
Julie B. Kampf
Director
Jun 2, 2025Option exercise+82,875––82,875
Marshall A. Hayward
Chief Scientific Officer, Director
Jun 2, 2025Option exercise+399,402––2,770,077
Marshall A. Hayward
Chief Scientific Officer, Director
Jun 2, 2025Option exercise+389,793––2,370,675
Alexander Gustaf Erik Rosen
Chief Administrative Officer
Jun 2, 2025Option exercise+96,608––617,411
Alexander Gustaf Erik Rosen
Chief Administrative Officer
Jun 2, 2025Option exercise+164,553––520,803
Holger Weis
Director
Jun 2, 2025Option exercise+85,800––96,581
Saleem Elmasri
CFO and Secretary
Jun 2, 2025Option exercise+66,293––66,239
Alison D. Silva
Pres + Chief Business Officer, Director
Jun 2, 2025Option exercise+110,227––110,227
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 2, 2025Option exercise+476,070––11,067,476
Christer Rosen
CEO and Chairman, Director, 10% owner
Jun 2, 2025Option exercise+497,396––10,591,406
Allison W. Brady
Director
Jan 22, 2025Option exercise+21,750––21,750
Holger Weis
Director
Jan 22, 2025Option exercise+10,781––10,781

Awards, option exercises, tax withholding and gifts are shown alongside open-market buys and sales. Each name links to the filing on SEC EDGAR.

Short interest

Shares sold short and not yet bought back, as of Oct 30, 2026 (FINRA, reported twice a month)

Short % of shares outstanding
3.26%
0M shares short
Days to cover
1.4
At 0M shares a day
Change since last report
-34.9%
From 0M shares
Short volume, 20 days
39.1%
Of volume reported to FINRA

Shares sold short, last 12 months

Short sale volume counts trades marked short on any given day, including market-maker hedging, so it runs far higher than the share of Jupiter Neurosciences's stock actually held short. Settlement fails (shares not delivered on time) peaked at 285,557 shares on Aug 24, 2026 over the last 90 days.

See a number that looks wrong?